Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$2.36 USD
-0.15 (-5.98%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $2.36 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value A Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AYTU 2.36 -0.15(-5.98%)
Will AYTU be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AYTU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AYTU
Agilent Technologies (A) Surpasses Q3 Earnings and Revenue Estimates
AYTU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AYTU
Aytu BioPharma to Present at Upcoming October 2025 Conferences
The technical outlook for AYTU is unchanged after it rises 5.91% on October 9
AYTU rises 0.42% on October 8, leaving the technical picture intact
AYTU Crossed Above 50 Day Moving Average on October 7
Aytu BioPharma management to meet with Lake Street